Patent US2502171A successfully refreshed from Google Patents.
US5208019A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Use of gamma-interferon for the treatment of vascular stenosis
Assignee: Genentech Inc
•
Filing: 1989-09-27
•
Granted: 1993-05-04
•
Expires: 2009-09-27
Abstract
Abstract The present invention relates to the use of gamma-interferon for the preparation of a pharmaceutical preparation for the treatment of vascular stenosis caused by e.g. intimal hyperplasia, including the treatment of restenosis following treatment of arterial stenosis or occlusion. In a preferred embodiment the present invention relates to the use of gamma-interferon for the treatment of arterial stenosis following vascular surgery and/or angioplasty.
Inventors
- 👤 Goran Hansson
- 👤 Jan Holm
- 👤 Lena Jonasson
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 15:48
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/19; A61K38/21; A61K38/217; A61P; A61P9/00; A61P9/10
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
43 words
A method of using gamma-interferon for the treatment of vascular stenosis, wherein gamma-interferon is administered to a patient having vascular stenosis in a pharmaceutical preparation containing said interferon in a sufficient amount to inhibit growth or proliferation activity of arterial smooth muscle cells.
Claim 2
Independent Claim
43 words
A method of using gamma-interferon for the treatment of vascular stenosis, wherein gamma-interferon is administered to a patient having vascular stenosis in a pharmaceutical preparation containing said interferon in a sufficient amount to inhibit growth or proliferation activity of arterial smooth muscle cells.
Claim 3
Dependent Claim
28 words
The method of using gamma-interferon according to claim 1, wherein the treatment of vascular stenosis is the treatment of restenosis following the treatment of arterial stenosis or occlusion.
Claim 4
Dependent Claim
25 words
The method of using gamma-interferon according to claim 2, wherein the treatment of restenosis is the treatment of arterial stenosis following vascular surgery and/or angioplasty.
Claim 5
Dependent Claim
11 words
The method of claim 1 wherein the gamma-interferon is desCysTyrCys gamma-interferon.
Claim 6
Dependent Claim
23 words
The method of claim 4 wherein the last four (4) C-terminal residues of the full length sequence of the desCysTyrCys gamma-interferon are deleted.
References Cited (Backward Citations)
US5096705A
Cited
US4483849A
Cited
US4680175A
Cited
US4946674A
Cited
US4897264A
Cited
US5026544A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-05-03 | 1996-11-02 | 1997-05-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-05-03 | 2000-11-02 | 2001-05-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-05-03 | 2004-11-02 | 2005-05-04 | $7700.00 | Window Closed / Lapsed |